Comparison · NCT01896479-sae
Cabozantinib (XL184) 60 mg vs Cabozantinib (XL184) 140 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cabozantinib (XL184) 60 mg vs Cabozantinib (XL184) 140 mg: serious adverse events. Trial comparisons, record NCT01896479-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01896479-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.447 | 0.362 | 0.535 | wilson | |
| Risk in group 2 | 0.5 | 0.413 | 0.587 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0528 | -0.174 | 0.0708 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.894 | 0.687 | 1.16 | log | |
| Odds ratio, group 1 over group 2 | 0.809 | 0.49 | 1.33 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Cabozantinib (XL184) 60 mg than on Cabozantinib (XL184) 140 mg | 18.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 60 mg tablets were administered with cabozantinib-matched placebo capsules orally once a day. | 55 | 123 | EG000 |
| Group 2 | Cabozantinib (XL184) 140 mg | Cabozantinib (XL184) 140 mg capsules were administered with cabozantinib-matched placebo tablets administered orally once a day. | 62 | 124 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first dose to 30 days following last dose (up to a maximum of 61 months)
Source ClinicalTrials.gov
Trial
- Title
- A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
- NCT number
- NCT01896479
- Phases
- PHASE4
- Conditions
- Medullary Thyroid Cancer
- Interventions
- Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg, Placebo tablet, Placebo capsule
- Lead sponsor
- Exelixis
- Results first posted
- 2025-09-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01896479?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01896479-sae